Nice recommends Roche's MabThera CSL Recruitment New draft guidance from the National Institute for Health and Care Excellence (Nice) has recommended the Roche drug MabThera (rituximab) as a treatment for adults with a rare type of vasculitis. The drug is licensed for bringing on remission in people ... |
